Your browser doesn't support javascript.
loading
Natural and hybrid immunity after SARS-CoV-2 infection in children and adolescents.
Rothoeft, T; Maier, C; Talarico, A; Hoffmann, A; Schlegtendal, A; Lange, B; Petersmann, A; Denz, R; Timmesfeld, N; Toepfner, N; Vidal-Blanco, E; Pfaender, S; Lücke, T; Brinkmann, F.
Afiliação
  • Rothoeft T; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany. tobias.rothoeft@rub.de.
  • Maier C; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Talarico A; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Hoffmann A; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Schlegtendal A; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
  • Lange B; Department of Epidemiology, Helmholtz Centre for Infection Research, Brunswick, Germany.
  • Petersmann A; University Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Oldenburg, Oldenburg, Germany.
  • Denz R; University Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
  • Timmesfeld N; Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University Bochum, Bochum, Germany.
  • Toepfner N; Department of Medical Informatics, Biometry and Epidemiology, Ruhr-University Bochum, Bochum, Germany.
  • Vidal-Blanco E; Department of Pediatrics, Faculty of Medicine, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.
  • Pfaender S; Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.
  • Lücke T; Department of Molecular and Medical Virology, Ruhr University Bochum, Bochum, Germany.
  • Brinkmann F; University Hospital of Pediatrics and Adolescent Medicine, St. Josef-Hospital, Ruhr-University, Bochum, Germany.
Infection ; 52(4): 1449-1458, 2024 Aug.
Article em En | MEDLINE | ID: mdl-38499828
ABSTRACT

PURPOSE:

In contrast to adults, immune protection against SARS-CoV-2 in children and adolescents with natural or hybrid immunity is still poorly understood. The aim of this study was to analyze different immune compartments in different age groups and whether humoral immune reactions correlate with a cellular immune response.

METHODS:

72 children and adolescents with a preceding SARS-CoV-2 infection were recruited. 37 were vaccinated with an RNA vaccine (BNT162b2). Humoral immunity was analyzed 3-26 months (median 10 months) after infection by measuring Spike protein (S), nucleocapsid (NCP), and neutralizing antibodies (nAB). Cellular immunity was analyzed using a SARS-CoV-2-specific interferon-γ release assay (IGRA).

RESULTS:

All children and adolescents had S antibodies; titers were higher in those with hybrid immunity (14,900 BAU/ml vs. 2118 BAU/ml). NCP antibodies were detectable in > 90%. Neutralizing antibodies (nAB) were more frequently detected (90%) with higher titers (1914 RLU) in adolescents with hybrid immunity than in children with natural immunity (62.5%, 476 RLU). Children with natural immunity were less likely to have reactive IGRAs (43.8%) than adolescents with hybrid immunity (85%). The amount of interferon-γ released by T cells was comparable in natural and hybrid immunity.

CONCLUSION:

Spike antibodies are the most reliable markers to monitor an immune reaction against SARS-CoV-2. High antibody titers of spike antibodies and nAB correlated with cellular immunity, a phenomenon found only in adolescents with hybrid immunity. Hybrid immunity is associated with markedly higher antibody titers and a higher probability of a cellular immune response than a natural immunity.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Imunidade Humoral / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 / Imunidade Celular / Anticorpos Antivirais Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Neutralizantes / Imunidade Humoral / Glicoproteína da Espícula de Coronavírus / SARS-CoV-2 / COVID-19 / Imunidade Celular / Anticorpos Antivirais Idioma: En Ano de publicação: 2024 Tipo de documento: Article